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Abstract: Exercise-associated hyponatremia (EAH) is dilutional hyponatremia, a variant 
of inappropriate antidiuretic hormone secretion (SIADH), characterized by a plasma 
concentration of sodium lower than 135 mEq/L. The prevalence of EAH is common in 
endurance (<6 hours) and ultra-endurance events (>6 hours in duration), in which both 
athletes and medical providers need to be aware of risk factors, symptom presentation, and 
management. The development of EAH is a combination of excessive water intake, 
inadequate suppression of the secretion of the antidiuretic hormone (ADH) (due to non 
osmotic stimuli), long race duration, and very high or very low ambient temperatures. 
Additional risk factors include female gender, slower race times, and use of nonsteroidal 
anti-inflammatory drugs. Signs and symptoms of EAH include nausea, vomiting, 
confusion, headache and seizures; it may result in severe clinical conditions associated 
with pulmonary and cerebral edema, respiratory failure and death. A rapid diagnosis and 
appropriate treatment with a hypertonic saline solution is essential in the severe form to 
ensure a positive outcome. 
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1. Introduction 
Exercise-associated hyponatremia (EAH) typically occurs during or up to 24 hours after prolonged 
physical activity, and is defined by a serum or plasma sodium concentration below the normal range of 
135 mEq/L [1]. It is also reported to happen in individual physical activities or during organized 
endurance events carried out in austere environments, in which medical care is limited or often not 
available, and patient evacuation to definitive care is often greatly delayed [2]. Rapid recognition and 
appropriate treatment are essential in severe forms to ensure a positive outcome [2]; however, few 
randomized trials concerning EAH treatment have been reported [3]. 
EAH was first described in Durban, South Africa, in 1981; subsequently, Noakes et al. in 1985 
described the occurrence of severe hyponatremia in four athletes who participated in endurance events 
that were longer than 7 hours [4]. EAH has been reported after sustained physical exertion during 
marathons, triathlons, and long-distance hikes, and by trekkers, climbers, and cold climate endurance 
athletes. Furthermore, it is likely that symptomatic or asymptomatic EAH is underreported in  
the literature [5–10]. 
2. Epidemiological Aspects 
The described prevalence of EAH varies widely, in some measure because the diagnosis is based 
solely on abnormal biochemical results in an appropriate clinical setting. Many cases of EAH may be 
asymptomatic and are largely detected from blood samples taken from permitting athletes participating 
in research screening protocols; reported prevalence ranges from 0%–51% [2]. The highest prevalence 
of “asymptomatic” hyponatremia has been noted in ultra-marathon races covering 161 km in North 
America, in which the impact of EAH has ranged between 30% and 51% [7,10,11]. The prevalence of 
“asymptomatic” EAH is greater than that of “symptomatic” EAH; determinations of type rely on 
biochemical diagnosis of EAH in conjunction with clinical symptoms and signs [2]. Severe EAH 
results in a significant mental status change, which is caused by cerebral edema (exercise-associated 
hyponatremic encephalopathy, also defined as EAHE), and is sometimes associated with  
non-cardiogenic pulmonary edema [12]. Many studies confirmed that deaths can be directly attributed 
to complications associated with EAHE [13,14]. The overall prevalence of symptomatic EAH in all 
marathon participants is generally less than 1% [15], but the percentage of EAH observed in all 
symptomatic athletes seeking medical care has been reported to be higher than 23% in an Ironman 
Triathlon [16] and 38% in runners taking part in a marathon and an ultramarathon in Asia [17]. An 
increasing datum is that symptomatic EAH is now reported in much shorter distance events, such as 
half marathons [18] and sprint triathlons taking approximately 90 minutes [19]. Symptomatic cases of 
EAH have been reported with increased frequency in hikers and in the military. The described 
incidence of hyponatremia in Grand Canyon hikers seeking medical care from exercise-associated 
collapse or exhaustion was 16%, with an estimated impact rate between 2 and 4 per 100,000 persons. 
In 1993, clinically significant EAH in female hikers trekking through the Grand Canyon was first 
reported [5]. Since that initial case series, three separate case reports of symptomatic hyponatremia 
have been described in wilderness settings: the first involved a man trapped in a cold Alaskan 
environment [20], the second an athletic woman hiking at a low altitude in Nepal [6], and the third 
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describes a physically fit man participating in an 8-day guided trek in New Guinea [21]. More severe 
cases have been reported by Spano et al. [22] in the Sierra Nevada Mountains of California and by 
Severac et al. [9]. 
US military services have reported an increased trend of EAH cases, primarily in the Marine Corps 
and army infantry personnel; there has only been one definite case of death [23–25]. 
Generally, in ultra-endurance athletes, the prevalence of EAH does not exceed 10% [4,26]. The 
prevalence of EAH seems higher in ultra-endurance (>6 hours) than in endurance races [27,28]; 
however, there have been variable results in studies investigating the prevalence of EAH in 
ultramarathons and other ultra-endurance events. 
Knechtle et al. reported that the prevalence of EAH was no higher in ultra-endurance athletes 
compared to existing reports on marathoners and Ironman triathletes [29]. 
A study that investigated the prevalence of EAH in ultra-endurance athletes, such as ultra-mountain 
bikers (ultra-MTBers), ultra-runners, and mountain bikers (MTBers) in four races held in the Czech 
Republic, showed that 5.7% of the finishers developed post-race EAH with post-race plasma sodium 
of <135 mmol/L. The prevalence of EAH was higher in ultra-runners compared to ultra-MTBers [30]. 
Another study showed that EAH occurred in more than 50% of the finishers of a 161 km 
ultramarathon in California. Main outcome measurements of the study were pre-race and post-race 
body mass, total body water (TBW), extracellular fluid (ECF), and plasma sodium. Hyponatremia 
occurred in over half of the 161-km ultramarathon finishers but was not predicted by a change in body 
mass. The combination of pre-race TBW and percentage changes in TBW and ECF explained 87.5% 
of the variation in the incidence of hyponatremia [11]. Studies on EAH in ultra-running events in 
Switzerland [26] and New Zealand [31] reported a prevalence of 0% and 4%, respectively. The 
prevalence of EAH in ultra-MTBers (3.7%) and MTBers (7.1%) was also similar to studies of 
multistage MTB races in South Africa and in the Alps, in which fluid intake correlated negatively to 
race time [32,33]. 
Drinking behavior and the large amount of fluid available at the refreshment stations might give 
insights into why the prevalence of EAH is different in the different various disciplines [34]. It was 
observed that the faster athletes drank more than the slower ones [26,35]. 
Fluid intake was positively related to race performance and post-race plasma [Na+] was negatively 
associated with race performance [30].  
Hyponatremic marathoners consume fluids at a higher rate (0.84 L/h) compared to non-hyponatremic 
runners. In mountain bikers, fluid intake was relatively high compared to marathoners, but this volume 
is within the hourly drinking volume limits of 0.8 L/h recommended for endurance exercise [13]. The 
high intensity of race, the difficult terrain, and the impossibility of drafting may be the main reasons 
that mountain bikers drink rather little compared to other ultra-endurance athletes [33]. The low mean 
fluid intake may explain a lower prevalence of EAH in ultra-MTBers [35].  
A high prevalence of EAH was reported for open-water ultra-distance swimmers due to ingestion of 
water during the race [36] (Table 1). 
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Table 1. Prevalence of exercise-associated hyponatremia (EAH). 
Disciplines Subjects Prevalence of EAH References 
Marathoners  up to 22% [13,15,37,38] 
Ultra-marathoners 
Asymptomatic 30%–51% [7,10,11] 
Athletes seeking medical care 38% [17] 
Mountain bikers   7.1% [32] 
Ultra-mountain bikers  3.7% [33] 
Ironman triathletes   1.8%–28% [16,28,39] 
Hikers  16% [5,6,9,20–22] 
Military  
Indreased trend; one 
case of death 
[23–25] 
Swimmers 
Males 8% 
[36] 
Females 36% 
3. Physiopathology 
Two major mechanisms largely account for the development of EAH: 
- Excessive fluid intake 
- Impaired urinary water excretion, largely as a result of persistent secretion of antidiuretic hormone 
(ADH) (Figure 1). 
Figure 1. Physiopathology of EAH. 
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Excessive fluid consumption leading to weight gain is considered the principal cause of reduced 
plasma sodium, and previous studies in ultra-endurance events have shown an association between 
fluid intakes, changes in body mass, and plasma sodium. Over-hydration appears to be the principal 
risk factor for the development of EAH. This occurrence reflects upon the weight gain observed in the 
majority of athletes who become hyponatremic. Evident sodium and fluid loss through sweat occur 
with prolonged exercise, leading to a decrease in extracellular fluid volume (ECFV) and plasma 
volume. The “effective” plasma volume further decreases with the redistribution of blood to the 
exercising muscles (which is caused by metabolic, hydrostatic, and haemodynamic mechanisms) [40]. 
The issue of whether sweat sodium loss contributes to the development of EAH remains 
controversial. The concentration of sodium in sweat varies widely, but it is usually between 15 and  
65 mEq/L, and the volume of sweat varies from 250 mL/h to >2 L/h [41,42]. Although one might 
expect that hypotonic fluid losses from sweat would produce a rise in serum sodium, the development 
of hyponatremia following this occurrence has been attributed to hypotonic fluid replacement greatly 
exceeding fluid loss through sweat. The excessive concern over dehydration and hyperthermia may 
lead to excessive fluid intake among competitors [7,11]. 
This tendency toward aggressive hydration is illustrated by comparing the 1970 study documenting 
a rise in plasma sodium in eight runners who each consumed 500 mL of water to the 1985 study in 
which four runners ingested an average of 9 L of fluid over the same distance and experienced a 
decrease in plasma sodium to below 125 mEq/L [4,43]. Moderate intake of a carbohydrate clearly has 
been demonstrated to improve performance [44]. Although vigorous hypotonic fluid replacement 
blunts the decrease in plasma volume with exercise, a preferential expansion of intracellular fluid 
volume through osmotic equilibration leads to a relative total body water excess despite plasma 
volume depletion [45]. 
The overdrinking behavior seems to be supported by companies selling sports drinks. Moreover, 
these sports drinks (solutions enriched with mineral salts and ions, slightly less hypotonic than mineral 
water) do not prevent EAH [46]. 
Subjects with normal renal function and a regular diet can excrete about 500–1000 mL/h of  
water [47]. With the additional non-renal losses of water due to sweat and insensible fluid losses, 
athletes should be able to consume as much as 1000–1500 mL/h before developing water retention and 
dilutional hyponatremia. Thus, although fluid ingestion is necessary for the occurrence of EAH, it is 
not likely to be the only factor, except in those circumstances in which water intake is excessive  
(i.e., >1500 mL/h) [2]. Under normal circumstances, ingestion of excessive water should suppress 
ADH, leading to the production of diluted and high-volume urine (where urine has an osmolality as 
low as 50 mOsm/kg and a volume of 500–1000 mL/h). The failure to suppress ADH reduces the 
ability of the kidneys to excrete a water load. The available data support the concept that many athletes 
with EAH have submaximal suppression of ADH and an inappropriately high urine osmolality; this is 
similar to SIADH. There are several nonosmotic stimuli that lead to the secretion of ADH that may be 
operable in endurance athletes: intense exercise itself, nausea or vomiting, hypoglycemia, and 
nonspecific stresses, such as pain and emotion. The excess of ADH production is responsible for 
potentially significant hyponatremia and is recognized as a key factor for EAH [48–51]. 
Moreover, it has been suggested that cytokine release (IL-6) during muscular glycogen depletion 
could also be involved in the nonosmotic stimulation of ADH. The hypothesis that IL-6 is involved in 
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the pathogenesis of EAH has been confirmed in multiple studies [52]. In a rat sepsis model, IL-6 has 
been shown to reduce the expression of aquaporin-2, the target of ADH and ultimate regulator of water 
diuresis. A genetic predisposition to EAH, or severity of expression, may be related to single 
nucleotide polymorphisms of the promoter region for the IL-6 gene, as postulated in other 
inflammatory diseases [53]. Furthermore, prolonged endurance exercise induces an immune response, 
inflammatory and oxidative stress, as suggested by the evidence of an increase in levels of GSSG 
(oxidized glutathione) [54]. In marathon runners, 24 hours after the race, there is an increase in their 
white blood cell count with neutrophilia; these runners experience an increase of approximately  
30 times normal levels of IL-6 and about 20 times normal levels of CRP. The levels of IL-6 increase 
exponentially with the intensity and duration of exercise; as does rhabdomyolysis and the consequent 
increase in serum CK levels correlated with IL-6 levels [55]. 
Other factors may lead to hyponatremia in endurance athletes. In a study of endurance athletes 
running for an average of 6 hours with ad libitum fluid intake, it was noted that even with a mass loss 
of 3.8 kg, plasma sodium maintained its normal levels [46]. Despite the loss in plasma volume in these 
subjects, there were significant increases in brain natriuretic peptide levels (NT-BNP). These 
elevations may lead to excessive losses of urine sodium and raise the risk of hyponatremia [56]. 
A possible mechanism for the maintenance of a normal serum sodium level despite weight gain is 
the release of sodium from internal stores [49]. Up to 25% of the body’s sodium is bound in bone and, 
although not osmotically active, is potentially recruitable into an osmotically active form [57]. Thus, 
this pool could minimize the decrease in plasma sodium induced by over-hydration or, if not 
mobilized, exacerbate hyponatremia [58]. 
The absorption of water retained in the gastrointestinal tract at the end of a race has been suggested 
as a cause for an acute drop in plasma sodium concentration. This may account for a transient lucid 
period after finishing a race followed by the acute development of cerebral edema within about  
30 minutes after the competition [14]. 
In a study that reviewed medical records from marathoners (all participants in the 1998 Suzuki 
Rock “N” Roll Marathon), hyponatremic patients were compared to other runners with regard to race 
time, gender, clinical signs of dehydration, and use of NSAIDs. The study showed that hyponatremic 
runners reported drinking “as much as possible” during and after the race; they were less likely to have 
clinical signs of dehydration. An inverse relationship between initial plasma sodium and time of 
presentation was found, with a late presentation that predicts lower plasma sodium [45]. 
The breakdown of glycogen into smaller, more osmotically active molecules, such as lactate, during 
exercise initially increases cellular osmolality and shifts water into cells, leading to a rise in serum 
sodium. This may then be reversed within 5 minutes after the cessation of exercise, leading to a 
transient reduction in plasma sodium [59]. Variations in potassium balances that serve as effective 
osmoles may also affect the plasma sodium so that hypokalemia will lead to exacerbating 
hyponatremia [60]. Although the major risk factor for developing EAH is excessive water intake 
beyond the capacity for renal water excretion, risk factors for EAH also include low pace racing, 
prolonged exercise with a duration of more than four hours, low or high body mass, pre-exercise 
hyperhydration, the use of non-steroidal anti-inflammatory drugs (NSAIDs), and extremely hot or  
cold environments [16]. 
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In marathoners, Mettler et al. noted an association between change in body mass and change in 
post-race plasma sodium [37]. In 161 km ultra-marathoners, however, Lebus et al. [11] did not find 
any association between changes in body mass and changes in plasma sodium. Also, in these  
ultra-marathon runners, the change in body mass showed no association with post-race plasma sodium 
or with a change in plasma sodium. This finding is not in agreement with the recent findings in 
marathoners reported by Mettler et al. [37]. These authors demonstrated an association between  
post-race plasma sodium and post-race plasma osmolality, and they supposed that the increased plasma 
osmolality might be due to the increased activity of ADH [61]. 
It seems that females are more susceptible to developing EAH, in particular severe hyponatremia, 
and they may be more symptomatic with equivalent levels of hyponatremia [12,62,63]. 
In rats, estrogen blunts the drive to consume sodium, with salt deprivation, and it induces renal 
oxytocin receptor mRNA synthesis and affects osmoregulation. Estrogen and progesterone inhibit the 
function of the Na+-K+ ATPase [64–66].  
In humans, pregnancy hormones lower the thirst threshold, contributing to hypotonic volume 
expansion, while estrogen increases ADH secretion in post-menopausal females [67].  
The gender effect may also produce a different behavior, such as more pressing adherence to 
hydration advice, during exercise or during longer exercise times. Although the incidence of women 
with symptomatic hyponatremia seems to be greater than that of men, when adjusted for BMI and 
racing time, the gender difference has not been shown to be statistically significant [38].  
Along with other nonosmotic stimuli to ADH secretion, NSAIDs have been implicated as a risk 
factor in the development of EAH by potentiating the water retention effects of ADH in the  
kidney [39,68]. Inhibition of renal prostaglandin synthesis due to NSAIDs has deleterious effects on 
hemodynamic and renal function. Prostaglandins actually antagonize the effect of ADH and modulate 
renal salt and water excretion [14,69,70]. However, there is conflicting data, and further investigation 
is necessary to determine whether NSAID treatment, with respect to both classification and dosages, is 
a sure risk factor for the development of EAH. Other drugs associated with SIADH, such as selective 
serotonin reuptake inhibitors, may also increase the risk of EAH, but up to now, the data is  
not conclusive [2].  
Exercise may also lead to rhabdomyolysis. This event has been associated with the use of diuretics, 
psychogenic polydipsia, and extreme exercise with water intoxication [71,72]. Subjects with cystic 
fibrosis may be at increased risk of rhabdomyolysis during exercise, considering their propensity for 
dehydration and hyponatremia by sodium loss via sweat through a defective chloride ion transport 
channel, the CF transmembrane conductance regulator (CFTR) [73]; in a recent study, CFTR 
mutations were found not to be associated with the development of EAH [74]. 
4. Clinical Aspects 
Signs and symptoms of EAH include nausea, vomiting, confusion, headache, seizures, and it may 
result progressively, together with severe clinical conditions associated with cerebral edema, in 
brainstem compression, pulmonary edema, respiratory failure, and even death. Symptomatic EAH 
should be defined qualitatively in two subgroups: “mild” or “severe” differentiated by the presence or 
absence of neurologic manifestations. Although the early symptoms of EAH may be nonspecific, the 
J. Clin. Med. 2014, 3 1265 
 
presence of altered mental states, comas, seizures or respiratory distress indicates exercise-associated 
hyponatremic encephalopathy (EAHE) and should be promptly recognized. An interesting report 
underlined the importance of maintaining a broad differential diagnosis when evaluating a subject with 
altered mental status in an alpine setting. Despite an initial presumed diagnosis of altitude sickness, 
after an exact diagnostic evaluation, the symptoms appeared to be related to symptomatic hypotonic 
hyponatremia [22]. Symptomatic EAH in an endurance athlete may be confounded with profound 
dehydration, necessitating intravenous rehydration. The severity of EAH establishes fluid choices; the 
two categories reflect different intravenous fluid treatment options. Bennett reasonably points out that 
dehydration may be misdiagnosed as EAH. The Wilderness Medical Society practice guidelines affirm 
that administration of isotonic fluids could be “disastrous” in athletes with EAH; it may actually 
worsen hyponatremia, and may have potentially “devastating” consequences [2]. 
5. Prevention and Treatment 
The primary strategy in preventing EAH is to avoid overdrinking during a race. Fluid ingestion, 
based on the sensation of thirst, during a race seems to be a prevention strategy because it reduces the 
risk of dehydration and over-hydration. Another strategy that has been shown to reduce the incidence 
of hyponatremia during endurance events is to reduce the availability of fluids along the routes of races 
(>3 km apart) [2]. In athletes who drink beyond thirst or fully replace 100% of body weight losses 
during a race, supplemental sodium may attenuate the reduction in plasma sodium concentration,  
but will not prevent the development of hyponatremia if overdrinking continues [75]. The monitoring 
of body weight change is a strategy commonly used in 161 km ultramarathons to prevent 
overhydration [7]. EAH has been reported with substantial weight loss in some environments, so 
weight loss should not exclude the diagnosis of EAH. Body weight can be monitored in organized 
events, and in the presence of weight gain during racing, fluid and sodium intake should be reduced 
until weight returns to between 2% and 4% of body weight loss from the baseline level [2].  
The ingestion of sodium during exercise may be useful to performance by maintaining the plasma 
volume and/or by attenuating reduction in blood sodium. However, until now, the influence of sodium 
ingestion during a race or performance seems inconclusive [76]. 
Vrijens and Rehrer [77] showed improved time to exhaustion and attenuated plasma sodium drops 
with the ingestion of 61 mmol sodium (18 mmol L−1 solution), compared to a placebo drink (distilled 
water), during 3 hours of cycling in the heat. Anastaiou et al. showed that even small amounts of 
sodium (19.9 mmol/L; 39.8 mmol in total) ingested during three hours of racing in the heat were 
sufficient to attenuate the decrease in plasma sodium [78]. Similar findings were observed by 
Twerenbold et al. [79] during a four hour running time trial in temperatures ranging from 5–19 °C. 
Again, sodium ingestion (25 mmol h−1, 100 mmol total) resulted in a smaller decrease in the plasma 
sodium concentration from pre- to post-run measurements in female athletes. Conversely, Barr et al. 
reported no differences in the plasma sodium concentration at the end of 6 hours of racing in the heat, 
when either a water or saline solution was ingested. They therefore postulated that the reasons for the 
lack of differences between the two trials were due to changes in extracellular/intracellular fluid 
volumes or to the incomplete absorption of sodium by the intestine [80].  
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Two studies have also investigated sodium supplementation during Ironman races and both  
reported no differences between those taking sodium supplements and those without sodium 
supplementation [75,81]. A recent study aimed at investigating the effect of a sodium supplement on 
endurance performance during a 72 km road cycling time-trial in cool conditions did not show any 
effect on time-trial performance or plasma sodium. However, plasma sodium is influenced by  
fluid intake [82]. 
Appropriate management of EAH depends firstly on correctly diagnosing the condition. In fact, 
EAH can be mistaken for dehydration, heat illness, or acute altitude illnesses (Table 2). When EAH is 
considered in the differential diagnosis of a collapsed athlete and a point of care sodium concentration 
analysis is available, the field diagnosis of EAH becomes straightforward [2]. On-site analysis of 
plasma sodium concentration is not widely available, and large and established events often have no 
capacity for on-site blood analysis. If EAH is clinically suspected, an assessment of volume  
status should be considered before the treatment with intravenous fluids is carried out. An 
inappropriate intravenous fluid administration could result in worsening hyponatremia with potentially 
devastating consequences [2].  
Table 2. Signs and symptoms of differential diagnosis (adapted from [2]). 
Signs and symptoms EAH Heat illness AMS HACE or HAPE
Fatigue/weakness +/− +/− + + 
Increased thirst +/− + +/− +/− 
Temperature elevated +/− +++ − − 
Tachycardia +/− + +/− +/− 
Nausea/vomiting +/− +/− +/− +/− 
Headache/dizzines +/− +/− +++ +++ 
Blurred vision +/− +/− +/− +/− 
Confusion/disorientation +/− +/− +/− +/− 
Obtundation +/− +/− +/− +/− 
Seizure +/− +/− +/− +/− 
Coma +/− +/− +/− +/− 
Respiratory distress +/− − +/− +/− 
Oliguria +/− + +/− +/− 
EAH, exercise-associated hyponatremia; AMS, acute mountain sickness; HACE, high altitude cerebral 
edema; HAPE, high altitude pulmonary edema; +/−, Possible; +, likely; +++, present; −, not present;  
The clinical signs that justify transfer to an emergency unit are in bold. 
The perception that heat exhaustion is caused by dehydration and that the levels of dehydration 
observed in endurance sports must be treated immediately with intravenous fluids has been termed the 
“dehydration myth” and has endured for over a decade. Nevertheless, in endurance athletes, there have 
been observed body mass losses of 8% or greater without clinical symptomatology or adverse 
consequences [7]. In most cases, such levels of dehydration are not dangerous and rarely require 
intravenous rehydration, if oral fluids can be tolerated. Furthermore, transient postural hypotension is 
common in endurance athletes receiving post-event medical therapy [83]. This is caused by lower 
extremity blood pooling (once the athlete stops moving) and the consequent impairment of cardiac 
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baroreceptor reflexes. These athletes show lightheadedness, dizziness, or syncope, and have been 
managed for dehydration or hyperthermia by race event medical providers [83].  
A high clinical supposition of EAH requires fluid restriction and salt supplementation. However, 
fluid restriction is contraindicated in the case of dehydration and rhabdomyolysis (with impending 
acute kidney injury). Intravenous hypertonic saline (HTS) is an appropriate approach in suspected 
EAH with neurological deterioration, whereas an oral hypertonic saline solution would be an 
appropriate approach in suspected mild EAH. When possible, urine analysis for sodium and 
osmolality, and blood analysis for osmolality, should be obtained before the start of treatment [2]. 
Subjects with EAH who are neurologically stable can be advised to limit fluid intake and consume 
salty snacks, soups, or a small volume of hypertonic fluid until the onset of diuresis. Oral hypertonic 
saline solutions are an appropriate intervention in subjects with EAH when oral intake is possible. If 
the subject is unable to tolerate oral intake, or when there is no improvement, or when symptoms 
worsen with this therapy, the recommended treatment is a 100 mL bolus of 3% hypertonic saline 
infused through a peripheral vein in less than 60 seconds. If the initial treatment does not improve the 
patient’s condition, sodium level and clinical assessments should be performed to identify signs of 
cerebral and/or non-cardiogenic pulmonary edema. These are the key factors that will determine 
whether a transfer to an emergency unit for urgent treatment is required. Organized endurance races 
that do not have an on-site opportunity for the measurement of plasma sodium concentration and 
treatment with hypertonic saline should prearrange an appropriate emergency transport system [2].  
In subjects with suspected EAH, and especially in those with an altered mental state, sodium 
estimation should be obtained as rapidly as possible after arriving at the hospital. The intent of field 
management is to stabilize the subject until their management can be transferred to a definitive care 
medical center [12]. Treatment of serious EAH involves the administration of a 3% HTS at 1 mL/kg/h, 
that is subsequently adjusted according to the sodium status. Increases of sodium to 1 mmol/L/h during 
the first 6 hours, 9 mmol/L during the first 24 hours, and 18 mmol/L during the first 48 hours  
are acceptable. Ideally, sodium levels should not exceed 20–25 mmol/L during the first  
48 hours [84] (Figure 2). 
Small-volume boluses of intravenous HTS are the recommended therapy for exercise-associated 
hyponatremic encephalopathy (EAHE). Failure to properly diagnose and treat EAHE has been 
associated with significant morbidity and death. Current consensus statement guidelines recommend 
up to three 100/mL boluses of 3% HTS spaced at 10 minutes intervals to correct symptoms [2]. Advice 
is unclear regarding the maximal volume that can be safely administered in a given time period beyond 
these initial boluses. Data from previous literature suggest that the majority of subjects showed 
symptom resolution with these initial boluses [51]. However, use of large volumes of 3% HTS, from 
600–950 mL, have produced no reported adverse outcomes [85,86].  
Several reports demonstrated the potential adverse consequences of intravenous, normotonic 
solution hydration and the benefits of HTS for athletes with EAH. Another case report provides further 
support for our concern about the potential dangers of intravenous normotonic solution hydration in 
EAH [4]. In a report [87] regarding two overhydrated ultramarathon runners with symptomatic EAH, 
one received an intravenous normotonic solution and was hospitalized for 5 days, including for  
36 hours in a semicomatose state. The other received intravenous 3% HTS and was fully alert within  
3 hours and discharged after 8 hours. Davis et al. [45] describe a retrospective and prospective analysis 
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of EAH treatment. The retrospective analysis involved 11 overhydrated marathon runners with severe 
EAH treated initially with intravenous normotonic solution; five of these runners (plasma sodium 
concentration range of 119–121 mEq/L) required hospitalization and three required intubation as well. 
Two of these subjects ultimately received HTS in the intensive care unit. The prospective trial 
involved four cases of overhydrated marathon runners with severe EAH (plasma sodium concentration 
range of 117–123 mEq/L) treated with 3% HTS; none required hospitalization, and the rate of plasma 
sodium correction with HTS was shown to be more rapid than for those runners who were treated with 
a normotonic solution [45]. Siegel et al. describes four marathon runners who became unresponsive, as 
if suffering from EAH; the two subjects that were treated with intravenous normotonic saline died with 
evidence of cerebral edema on postmortem examination. In contrast, in the two runners who received 
3% HTS, the treatment caused a rapid neurologic improvement without adverse effects [48]. 
Figure 2. Algorithm for treatment of EAH. EAH, exercise-associated hyponatremia; HTS, 
hypertonic saline. 
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If neurologic impairment is present, HTS is the most effective agent and NS should be avoided. 
Subjects with EAH encephalopathy have been shown to recover more quickly when treated with  
3% HTS versus isotonic saline and have a significantly reduced morbidity and mortality rate [48]. 
Furthermore, there is little data concerning oral hypertonic saline solutions. Considering whether or 
not it is useful to “asymptomatic” cases of EAH, the decision seems to be complicated by evidence 
that in clinical settings, the percentage of athletes with biochemical hyponatremia at the race finish 
who later progress to life-threatening hyponatremic encephalopathy and non-cardiogenic pulmonary 
edema is currently unknown. The efficacy of oral and intravenous 3% saline solution for treatment of 
“asymptomatic” clinical conditions needs further critical investigation. The clinical efficacy of an oral 
hypertonic solution in the treatment of EAH-induced delirium has been documented in three marathon 
runners [88]. In a large, randomized controlled trial set up to compare the efficacy of oral versus 
intravenous 3% HTS, in biochemical (non-neurological) cases of EAH, both oral and intravenous 
administration of a 100 mL bolus of 3% HTS are associated with a similar increase in plasma sodium 
without adverse consequences. The main physiological difference between the routes of administration 
was a significant plasma volume expansion with the intravenous (9%), but not the oral (1%) 
administration of HTS. It has been previously documented that intravenous 3% HTS elicits a greater 
plasma volume expansion compared to intravenous isotonic saline solution. Oral HTS is the 
intermediate treatment of choice for athletes diagnosed with EAH without significant symptoms [89]. 
6. Conclusions  
Exercise-associated hyponatremia is still an underdiagnosed complication of endurance sports. 
EAH has a complex pathogenesis and a multifactorial etiology. Although hyponatremia is often mild 
and corrects itself without significant intervention, the development of neurologic sequelae suggests 
EAHE (altered mental status, seizures, coma, and death). Failure to rapidly diagnose and properly treat 
EAHE or pulmonary edema has resulted in death in otherwise young, healthy individuals. 
Preventing EAH is the key factor in protecting participants in endurance events and other 
wilderness activities. There is a need to develop more rational fluid replacement strategies and 
education to optimize, rather than maximize, fluid intake during extreme exercise. Currently, there is 
no one recommendation that fits all individuals for fluid and salt consumption during endurance 
events, although prudent general guidelines include drinking to thirst and specifically avoiding 
excessively high fluid intake and monitoring body weight to avoid weight gain during a race. The 
serum sodium level and a rapid clinical assessment for signs of cerebral edema are the key factors that 
will determine urgent treatment with hypertonic saline solution. 
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